Deciphera Pharmaceuticals will likely be pumped by the IPO underwriters soon now that the quiet period has ended.
Cantor Fitzgerald really went out high on Progenics Pharmaceuticals, or did they? Needham and Company also gave this stock its highest Strong Buy rating too.
Verastem stock had a price target set 364% higher than its current price by Cantor Fitzgerald. Cantor Fitzgerald has a buy rating on the stock. Verastem is on track for duvelisib
Exelixis stock has done a candle over candle reversal off of its uptrend line support which looks like a good swing trade setup. Exelixis stock popped with the FDA approval
Sorrento Therapeutics Inc has bounced off its 61.8 percent Fibonacci retracement level. Sorrento Therapeutics had a decline in short interest in the month of September. As of September 29th, there
Verastem Inc price target was raised to $17 by Cantor Fitzgerald last week. The new $17 price target represents 330% upside from the previous close of $3.95. Cantor has a
The FDA has granted priority review for Exelixis Cabomteyx. The sNDA seeks approval of Cabometyx for patients with previously untreated advanced renal cell carcinoma (RCC). The FDA determined the sNDA
Exelixis stock looks like a good technical setup. The stock is oversold and looks to be trading inside a larger uptrending continuation pattern on the chart. Exelixis Inc is a
CAR T stocks are the buzz right now. Even grocery store workers are talking about the FDA approval of the first CAR-T therapy from Novartis last week. Labiotech wrote about
Big news: Novartis FDA Car T approval is likely coming soon after a Food and Drug Administration advisory panel unanimously recommended approval for Novartis's leukemia drug tisagenlecleucel. The FDA usually